Renal Impairment, CI-AKI Risk & Metformin Management

Association and causation

An acute kidney injury after contrast is contrast-associated AKI (CA-AKI): the timing alone does not establish that contrast caused the injury. Contrast-induced AKI (CI-AKI) describes the smaller causal subset. Hospitalized patients may have dehydration, sepsis, hypotension, obstruction, medications, or surgery that explain worsening renal function independently of contrast. Calling every creatinine rise “contrast nephropathy” can lead to withholding a useful examination while overlooking the actual cause.

The technologist identifies risk factors, checks the available laboratory information, and escalates concerns to the radiologist or prescribing team. The decision compares the diagnostic benefit of enhancement with renal and other risks. An urgent examination can be appropriate even in severe renal impairment; there is no universal creatinine concentration above which iodinated contrast must never be given.

ACR metformin categories

Interpreting eGFR and AKI

Estimated glomerular filtration rate is a more useful screening measure than an isolated serum creatinine in a patient with stable renal function. It depends on the estimating equation and patient characteristics. Serum creatinine can lag behind an acute change in function, so a seemingly reassuring eGFR does not exclude AKI. Trends, recent clinical events, urine output, and the clinical history matter.

Screen for known kidney disease, prior renal surgery, dialysis, previous AKI, and other risks specified by local policy. Determine whether a laboratory result is recent enough for the patient's situation. An inpatient whose condition has changed may require a new assessment even when an older outpatient result was acceptable. Do not infer a fixed laboratory-validity interval from an exam question unless the policy is stated.

Stable patients with eGFR at least 30 mL/min/1.73 m² generally do not need prophylactic volume expansion solely for IV iodinated contrast. ACR recommends considering prophylaxis for AKI or severe chronic kidney disease with eGFR below 30, while weighing heart failure and other risks of volume expansion. For eGFR 30–44, prophylaxis may be considered individually when additional high-risk circumstances exist; it is not mandatory for every patient in that range.

Prevention and follow-up

Isotonic IV saline is the usual preferred volume-expansion method when prophylaxis is indicated. Timing, volume, and infusion rate are individualized by the treating clinician. A patient with pulmonary edema or decompensated heart failure can be harmed by a routine fluid-loading schedule. Oral hydration alone should not be presented as an established substitute for prophylaxis in AKI or severe chronic kidney disease.

Sodium bicarbonate has not demonstrated an advantage over saline and is not preferred by ACR because of preparation requirements. N-acetylcysteine is not recommended for IV-contrast renal prophylaxis. Mannitol and furosemide are not renal-protection treatments for this purpose. This does not mean a diuretic prescribed for an independent clinical indication must automatically be stopped by the technologist.

Use a diagnostically adequate contrast dose chosen by the radiologist. Reducing the dose until the study becomes nondiagnostic creates risk and may lead to another exposure. Record the agent, concentration, volume, route, and any adverse event. Follow-up testing is selected for the clinical situation rather than ordered automatically for every contrast recipient.

Dialysis patients

An anuric patient with end-stage renal disease does not have functioning renal tissue to injure in the usual way, but volume and osmotic loads still require consideration. A dialysis patient who retains meaningful urine output may have residual renal function worth protecting. ACR does not recommend initiating dialysis or changing its schedule solely because IV iodinated contrast was administered. Coordinate care with the responsible team rather than promising immediate dialysis will prevent an injury.

Metformin: the ACR categories

Metformin itself is not a nephrotoxic drug and does not increase the risk of CA-AKI. The concern is accumulation of metformin if significant renal dysfunction develops, which can contribute to lactic acidosis. Renal function and the procedure determine the precautions; taking metformin alone is not a contrast contraindication.

Under ACR guidance, a patient with no AKI and eGFR at least 30 may continue metformin for IV iodinated contrast. There is no obligatory post-contrast renal test solely because that patient takes metformin. In AKI, eGFR below 30, or an arterial catheter procedure that could send emboli to the renal arteries, metformin is held at or before the procedure and for 48 hours afterward. The clinician reassesses renal function before resuming it.

An IV CT angiogram is different from an intra-arterial catheter examination. Do not apply the embolic-risk rule to every examination whose name contains “angiography.” FDA labeling and some institutional policies are more restrictive than ACR; follow the authorized local policy and clarify differences with the clinician. The guide's categories identify the ACR recommendation rather than overruling an order.

Worked screening decisions

A stable patient with eGFR 36, no AKI, and metformin use does not automatically enter ACR Category II. Under ACR IV-contrast guidance, metformin can continue, and hydration is considered only if the broader risk assessment supports it. A patient with eGFR 26 or an active AKI needs clinician review, consideration of prophylaxis, and the Category II metformin precautions. The difference is the patient's renal condition, not the mere presence of diabetes on a checklist.

Reference: ACR Manual on Contrast Media.